Previous Close | 0.0093 |
Open | 0.0090 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0090 - 0.0110 |
52 Week Range | 0.0010 - 0.0158 |
Volume | 20,682,341 |
Avg. Volume | 46,449,119 |
Market Cap | 63.753M |
Beta (5Y Monthly) | 3.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0010 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation Plantation, Florida--(Newsfile Corp. - February 23, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on their work ...
Plantation, Florida--(Newsfile Corp. - February 12, 2021) - Nutra Pharma Corporation (OTC PINK: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they are focusing on their intellectual property portfolio and have engaged their IP attorneys at Christopher & Weisberg P.A."Intellectual property, including patents and trademarks, ...
Plantation, Florida--(Newsfile Corp. - January 12, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Letter to Shareholders on the Company's website."The last year was a challenging ...